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Ischemic cerebral stroke is a major cause of death and morbidity. Currently, no neuroprotective agents 
have been shown to impact the clinical outcomes in cerebral stroke cases. Here, we report therapeutic 
effects of Se nanoparticles on ischemic stroke in a murine model. Anti-transferrin receptor monoclonal 
antibody (OX26)-PEGylated Se nanoparticles (OX26-PEG-Se NPs) were designed and synthesized and 
their neuroprotective effects were measured using in vitro and in vivo approaches. We demonstrate 
that administration of the biodegradable nanoparticles leads to resolution of brain edema, protection 
of axons in hippocampus region, and myelination of hippocampal area after cerebral ischemic stroke. 
Our nanoparticle design ensures efficient targeting and minimal side effects. Hematological and 
biochemical analyses revealed no undesired NP-induced changes. To gain mechanistic insights into 
the therapeutic effects of these particles, we characterized the changes to the relevant inflammatory 
and metabolic signaling pathways. We assessed metabolic regulator mtoR and related signaling 
pathways such as hippo, Ubiquitin-proteasome system (ERK5), Tsc1/Tsc2 complex, FoxO1, wnt/β-
catenine signaling pathway. Moreover, we examined the activity of jak2/stat3 signaling pathways 
and Adamts1, which are critically involved in inflammation. Together, our study provides a promising 
treatment strategy for cerebral stroke based on Se NP induced suppression of excessive inflammation 
and oxidative metabolism.
Cerebral stroke has been considered as a major health concern1. By 2050 a growing number of people around the 
world will be aged 65 years or older which would lead to an increase in age related diseases including the stroke. 
Intense research is currently underway for developing preventive strategies, understanding the disease dynamics 
and mechanism, as well as for treatment of stroke and its associated disabilities2,3. Developing drugs that tar-
get the central nervous system (CNS) remains a major challenge for pharmaceutical science and industry. Fast 
metabolization, clearance from blood circulation and poor transport across the blood-brain barrier hamper the 
efficacy of most central nervous system drugs4. A major challenge in developing anti-stroke drugs is the complex-
ity of the signaling processes involved as well as the associated inflammatory response that further complicates 
the problem. In the mammalian CNSs, signaling networks including mTOR, Wnt/β-Catenin, Hippo-Yap-Mst, 
Jak-Stat affect neuronal growths and metabolisms5,6; dysregulation of these pathways during or after stroke results 
in neuronal damage and death7. Moreover, hippocampal neurogenesis, synaptic plasticity and memory consol-
idation are inhibited by pro-inflammatory cytokines8. Understanding these pathways enables rational targeting 
of selected pathways and leads to efficient therapeutic strategies with minimal side effects. Intense research is 
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underway to develop nanoparticle-based strategies for targeted therapy and drug delivery9,10. Targeted therapy by 
nano drug delivery systems has garnered much attention to treat various diseases such as cancer in recent years11–
15. Among these, Se nanoparticles emerged as promising tools for fighting major CNS disorders. Selenium (Se) 
is an essential trace element to human health with unique physiological and pharmacological properties which 
reduce the incidence of neurodegenerative diseases16,17. In fact, Se can participate in modulation of neurogenesis, 
electron transport chain dynamics, preservation of the redox balance, and regulation of the Ca2+ transport in the 
neural cells. High concentrations of the polyunsaturated fatty acids in the brain make it highly vulnerable to oxi-
dative stress18. Several Se nanoparticles have been developed and their applicability for neurological diseases has 
been tested. For instance, Epigallocatechin-3-gallate (EGCG)-stabilized Se nanoparticles (NPs) coated with Tet-1 
peptide could enhance recovery of Alzheimer’s disease through inhibition of amyloid-β aggregation, in vitro19. 
Se nanoparticles exhibit high antioxidant activity20 and selenoproteins reinforce endogenous antioxidant system. 
The selenoproteins are significantly expressed in the human brain and their inherent antioxidant activity con-
tributes to the free radical defense system and brain function. The expression of selenoproteins is associated with 
dietary Se intake. Furthermore, Se administration contributes to mitochondrial dynamics through an autophagy 
dependent mechanism after focal cerebral ischemia21. In this work, for the first time, we synthesized and studied 
the capability of OX26 antibody functionalized Se NPs (with sizes ~12 nm) for in-vivo targeted therapy of brain 
ischemic stroke in a Wistar rat model. This was justified based on recent reports indicating that the transferrin 
receptor (TfR) is highly expressed in brain capillary endothelial cells to facilitate entry of the iron transporting 
protein into the brain22. OX26 is a monoclonal antibody against the transferrin receptors, providing targeted drug 
delivery to the brain through a receptor-mediated transcytosis pathway23. We further studied the interaction of 
the Se NPs with interconnected signaling pathways including Tsc1/Tsc2 complex, FoxO1, mTORC1/mTORC2, 
Wnt/β-Catenin, Hippo-YAP-MST, USP and autophagy after focal cerebral ischemia-reperfusion. In addition, the 
regulatory effects of the Se NPs on the activity of Jak2/Stat3, Mst1, mTORC1, ADAMTS1 as well as apoptosis were 
evaluated after the focal cerebral ischemia reperfusion. Based on these investigations, we propose a model that 
explains the therapeutic effects of Se NP for cerebral stroke.
Results and Discussion
Synthesis, characterization, stability and particle-protein interactions of OX26-PEG-Se 
NPs. Figure 1a illustrates the method used for synthesis of the Se NPs. Changes in volume of 0.1 M selenious 
acid was resulted in synthesis of Se NPs with different sizes (Fig. S1). Then, the Se NPs were PEGylated and func-
tionalized by OX26 monoclonal antibody to obtain a targeting nanoparticulate system (Fig. 1b). Quantitation of 
the OX26 monoclonal antibody immobilized onto the surface of NPs was performed (Table S1). Various spectro-
scopic and microscopic methods were used to characterize the morphology, the physicochemical properties, and 
localization of the OX26-PEG Se NPs. Figure 1c–e presents the transmission electron microscopy (TEM) images 
of aggregated Se NPs and monodisperse spherical particles of OX26-PEG–Se NPs with an average diameter of 
~12 nm, which is further confirmed by dynamic light scattering (DLS, polydispersity 0.05) technique. The bare Se 
NPs were significantly aggregated due to their high surface energy, which in turn resulted in their precipitation 
at the bottom of the cuvette (Figs 1c and S2). Functionalization of the bare Se NPs with PEG-OX26 significantly 
increased their stability. To evaluate the effects of PEG-OX26 functionalization on the surface charge of the Se 
NPs, bare Se NPs and OX26-PEG-Se NPs zeta potential was measured. The average surface charge of bare Se 
NPs was approximately −24 mV, which converted to +1.17 mV after functionalization, thus a higher cellular 
uptake is expected for the OX26-PEG-Se NPs compared to the bare NPs. FTIR spectroscopy was used to confirm 
the chemical bonds formation between OX26 antibody and PEG-Se NPs. For the OX26-PEG-Se NPs, the peak 
at 1699 cm−1 confirmed the presence of OX26 protein on surface of the Se NPs (Fig. 1g–i), consistent with the 
previous reports24.
Next, we tested whether PEG-functionalization can suppress corona formation on the synthesized particles. 
Non-specific protein adsorption on the surface of the NPs may have profound effects on stability, biocompatibility 
and cellular uptake25. Hence, we investigated the changes in size distribution, polydispersity and zeta potential of 
the bare Se and OX26-PEG-Se NPs in both 10% human plasma and complete medium supplemented with 10% 
serum (cMEM). The results of the physicochemical characterizations are summarized in Tables S2–S5. The results 
showed that size distribution of the bare NPs dramatically shifted to higher values due to protein adsorption on 
their surface, while the PEG-functionalized NPs showed significantly lower size variations, suggesting a reduced 
affinity of the functionalized NPs for plasma proteins. Interactions of the synthesized particles with cells were also 
studied and corona formation was assessed. Previous studies showed that interactions between biomolecules in 
the corona and corresponding receptors in the cell membrane may affect the cell uptake of NPs, and therefore 
the cell survival26. Salvati and Dawson found that NP uptake in serum free (SF) condition resulted in cell damage 
by a strong adhesion of Silica NPs on the cell membrane27. Using rat PC12 cells and the human breast cancer 
(MCF7) cells, we evaluated cellular uptake of FITC-OX26-PEG-Se NPs and cell survival followed by oxygen 
glucose deprivation (OGD) at different times (Figs S3 and S4). When the FITC-OX26-PEG-SeNPs exposed to 
cells in SF condition, the particle uptake, cellular damage and cell death were found to be higher in comparison 
to those in the cMEM condition after 120 min incubation. Severe alterations in cell shape such as cell shrinkage 
and disintegration of cell-to-cell contacts are clearly observed by using fluorescence microscopy after 180 min in 
SF condition, indicating the initiation of the apoptotic and/or necrotic cell death. In fact, we did not observe any 
re-growth and/or cell viability after 180 min uptake (followed by a centrifugation at 2000 rpm and re-seeding of 
the cell). Surprisingly, the cMEM condition decreased the cell death after the OGD. In 360 min NP uptake (which 
followed by a centrifugation step at 2000 rpm), the cells were seeded again. We observed a good coordination of 
cell growth and division, suggesting not only lower uptake in the presence of serum, but also positive effect of 
the serum (possibly through formation of corona layer) on the essential antioxidant activity of the NPs in cul-
ture medium having oxidative stress conditions. Overall, since the necrotic cell death and chronic inflammation 
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are closely correlated with the inhibition of the hippocampal neurogenesis and memory dysfunction, we found 
suggestive evidences for a positive in vitro effect of protein corona on neuronal survival, under ischemic condi-
tions. In the next step, the uptake and internalization of the NPs by the PC12 cells were studied using TEM. As 
shown in Fig. 2a,b, OX26-PEG-SeNPs enclosed in vesicles and transported across the cell membrane, presumably 
through receptor-mediated endocytosis. The NPs seemed to be engulfed in early endosome or free in the cytosol. 
Astonishingly, our result confirmed that the localization of the NPs was in the nucleus (Fig. 2c,d). To directly 
assess the targeting capabilities of the Se-based NPs for neuronal cells, we performed the following flowcytom-
etry analysis. The PC12 cells were treated with Nerve growth factor (NGF) and 1% serum (1:100) for 5 days to 
differentiate into neural cells in vitro. When OX26-PEG-SeNPs were exposed to the cells in cMEM condition, 
significant uptake levels were observed for the OX26-PEG-SeNPs than the PEG-Se NPs at 37 °C at different times, 
indicating the targeting effect of the functionalized OX26 antibody (Fig. 2e). Then, in order to study whether the 
targeting capability of the OX26-PEG-SeNPs maintains in vivo, we evaluated the elemental Se distribution 24 h 
after intraperitoneal administration of the PEG-Se NPs and OX26-PEG-Se NPs by using ICP-OES analysis of 
brain, liver and kidney tissues (Fig. 2f). The Se content of kidney tissue was more than brain and liver in control 
and PEG-Se NPs groups. Strikingly, the selenium content of the brain increased compared to other tissues in 
OX26-PEG-Se NPs, confirming the in vivo targeting capabilities of the functionalized Se NPs.
Pharmacological efficiency. Growing evidences suggest that Se NPs can act as anti-tumor, anti-fungal and 
anti-bacterial agents, but it is not known whether these NPs can contribute to neuronal survival after stroke28–31. 
The major cause of neuronal cell death in ischemic brain injury is cellular swelling. Aberrant entry of Na+ ions 
increases the voltage-gated chloride channel activity, which in turn causes a sequential chain of high cytoplasmic 
level of sodium and chloride ions, osmotic imbalance and subsequently cytotoxic edema32. Here, we found that 
intraperitoneal administration of the OX26-PEG-SeNPs decreased the brain edema in Wistar rats subjected to 
30 min of middle cerebral artery occlusion (MCAO) and 22 h of reperfusion. In our study, brain water content 
was significantly increased in response to focal cerebral ischemia. The OX26-PEG-SeNPs significantly decreased 
brain water content compared to the MCAO and vehicle groups (Fig. S5). Moreover, the infarction volume 
was evaluated by using 2,3,5-triphenyltetrazolium chloride (TTC) staining method (Fig. 3a). Surprisingly, the 
OX26-PEG-Se NPs reduced infarction volumes. Compared with the MCAO and vehicle groups the stroke size 
was smaller in the OX26-PEG-Se NPs group.
Figure 1. Schematic illustration of reaction steps involved in the synthesis (a) and functionalization (b) of Se 
NPs are given. Representative TEM images of bare (c) and PEGylated (d,e) Se NPs are shown. Panel (f) presents 
the zeta potential of the bare and antibody functionalized Se NPs. Panels (g–i) are FTIR spectra of bare Se NPs, 
PEG-Se NPs and OX26-PEG-Se NPs respectively.
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To evaluate if the neuroprotective effect of the OX26-PEG-Se NPs may have clinical utility, the NPs were 
administered 1 h after stroke and neuronal density was determined by hippocampal Nissl staining (Fig. 3b). The 
neuronal density significantly fell throughout the hippocampus region in the MCAO group. The percentage 
reduction in neuronal density was significantly lower for the OX26-PEG-Se NPs treated group, suggesting the 
increased neuronal cell survival by the NPs under oxidative stresses. It is known that the hippocampus is rich in 
myelin than other gray matter regions33. Hence, in order to further investigate the effects of the OX26-PEG-Se 
NPs on neuronal survival, we have studied myelinated hippocampal area in different groups by the Luxol fast blue 
(LFB) technique (Fig. 3c). A significant decrease in the LFB density on ipsilateral brain sections was observed 
in the MCAO group compared with baseline, indicating extensive loss of myelin in the hippocampus region. 
However, for the OX26-PEG-Se NPs group, the LFB indicated a significant increase of density in the ipsilateral 
hemisphere. Later, we investigated whether induction of the MCAO affects the number of axons in hippocampus 
region. To assess the number of axons, the tissue sections were stained by Bielschowsky’s silver method. A signif-
icant reduction of hippocampal axon density in the MCAO group was observed (Fig. 3d).
Figure 2. TEM images of differentiated PC12 cells exposed to 100 μg/mL of OX26-PEG-Se NPs (25 nm in size) 
in cMEM for 1 h (a,b) and 3 h (c,d). The arrows show the major localization of the NPs within the nucleus. (e) 
Kinetics of uptake of 50 μg/mL of FITC-OX26-PEG-SeNPs (12 nm in size) and FITC-PEG-Se NPs in cMEM 
by differentiated PC12 cells at different times evaluated by flowcytometry (average of three replicates ± sd). (f) 
Comparison of elemental Se distribution in different tissues 24 h after intraperitoneal administration of PEG-Se 
NPs and OX26-PEG-Se NPs by ICP-OES analysis. The Se content of brain significantly increased in OX26-
PEG-Se NPs group compared to control and PEG-Se NPs at dose of ~1000 μg/mL. The symbols ***, ** (and 
also *), and # show the P-values of P < 0.001, 0.05, and 0.01 as compared to control, respectively.
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In contrast, the OX26-PEG-Se NPs could maintain the density of axons in hippocampus region. Parallel to the 
reductions in the infarction volumes, we also observed recovery of locomotor function by evaluation of neuro-
logic deficit scores and ladder test (Fig. S6).
Side effects and systemic toxicity. A great challenge of NP-based drugs is the probable emergence of 
side effects on short or long time scales34,35. Excessive Se is known to be associated with hepatic damage, diabetes, 
neurodegenerative and cardiovascular disease36. Therefore, to determine whether the Se-based.
NPs may have adverse effects; we investigated the emergence of systemic toxicity. First, we did not observe 
any change in the daily food intake due to NP administration (Fig. 4a). Second, we performed haematological 
analysis after administration of the OX26-PEG-Se NPs (1000 μg/mL at 1, 14 and 28 days) and evaluated red 
and white blood cells count and other haematological parameters (Fig. S7). Again, no significant differences 
were observed between the OX26-PEGSe NP and control groups. Third, we analyzed renal function because of 
commonly-observed significant uptake of nanoparticles by kidney. No significant increases in urea and creatinine 
levels were observed for the OX26-PEG-Se NP group as compared to the control one (Fig. 4a). Moreover, in order 
to study whether the OX26-PEG-Se NPs may involve in detrimental effects on liver, we measured the AST and 
ALT serum levels, as important indicators of the hepatic injury. Again, we did not observe a significant difference 
between the OX26-PEG-Se NPs and control groups (Fig. 4a). We also studied the effects of the OX26-PEG Se 
NPs on other organs, for which the serum LDH level and morphology of different tissues were evaluated. In this 
regard, the histopathological analysis of the heart, spleen, liver, kidney, lung and testis (in fact, our previous study 
Figure 3. (a) TTC staining which presents significant decrease of infarct volume (#p < 0.01 compared 
to MCAO group) by OX26-PEG-Se NPs. The non-infarcted brain tissue appeared red and the infarcted 
area appeared white. (b) Nissl staining of hippocampal CA1 subregion. Green and red arrows indicate 
intact and necrotic cells, respectively. The OX26-PEG-Se NPs significantly contributed to enhancement of 
neuronal survival under oxidative stress (*p < 0.001 and #p < 0.001 compared to control and MCAO groups, 
respectively). (c) LFB staining of hippocampal CA1 subregion. Myelinated fibers (blue), neutrophils (pink) 
and nerve cells (purple) are observable. The MCAO significantly decreases myelinated hippocampal area, 
while OX26-PEG-Se NPs administration significantly maintained myelinated hippocampal region (*p < 0.001 
and #p < 0.001 compared to control and MCAO groups, respectively). (d) Bielschowsky’s silver staining of 
hippocampal CA1 subregion. The OX26-PEG-Se NPs administration strongly maintained the number of 
axons in hippocampal CA1 subregion (*p < 0.0001 and #p < 0.0001 compared to control and MCAO groups, 
respectively, axons: black) (All scale bars are 200 μm).
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showed that testis is one of the organs with high uptake of NPs)37 showed no observable morphological damages 
after the OX26-PEG-Se NPs administration (either one day or 28 days after the injection (Fig. 4b–g for morpho-
logical aspects). These results demonstrated that the functionalized Se NPs can behave as biocompatible nanoma-
terials, without any Se-related side effects at the desired dose of 1000 μg/mL, for in vivo therapeutic applications.
Molecular targeting of OX26-PEG-Se NPs. In order to gain mechanistic insights into the observed 
therapeutic effect of the Se NPs, we studied pathways related to metabolism, oxidative stress and inflammatory 
response.
Targeting molecular pathways involved in cellular metabolic activity. The mammalian target of rapamycin 
(mTOR) is a key molecule that integrates multiple extracellular and intracellular signals to regulate cell sur-
vival. It has been shown that mTOR controls cellular energy consumption and its activity is altered in patholog-
ical conditions such is ischemic and oxidative stress38. In this regard, the impact of the OX26-PEG-Se NPs on 
targeting mTOR signaling pathways was studied by monitoring the activity of the Tsc1/Tsc2 complex, central 
negative regulator of mTORC1, and expression of Tsc1 and phosphorylation levels of Tsc2 proteins. The Tsc1 
protein induces protective autophagy and neuroprotection against focal cerebral ischemia via Tsc2 phosphoryl-
ation and subsequently mTORC1 suppression. The Tsc2 phosphorylation decreases mTORC1 activity through 
direct inhibition of the small GTPase Rheb (a positive regulator of mTORC1 complex)39. Here, the Tsc1 expres-
sion was found significantly higher in rat hippocampal cells exposed to the functionalized Se NPs + MCAO as 
compared to other groups (Fig. 5a). Likewise, to confirm whether the Tsc1 expression alters neuronal fate via 
an mTORC1-dependent mechanism, we determined the Tsc2 phosphorylation in rat hippocampal neurons. 
The total content of Tsc2 protein was not changed in different groups, whereas the Tsc2 phosphorylation was 
found higher in the functionalized Se NPs + MCAO as compared to other groups, indicating suppression of the 
mTORC1 activity (Fig. 5b). To find out the link between neuronal survival and mTOR signaling, we measured 
Figure 4. Study of potential adverse effects of Se of intraperitoneally administrated OX26-PEG SeNPs at dose 
of 1000 μg/mL by examining (a) daily food intake, haematological parameters (RBC and WBC levels) and 
biochemical factors (urea, creatinine, AST, ALT, LDH levels). No significant variations were observed for the 
groups exposed to OX26-PEG-Se NPs as compared to control ones after 1, 14 and 28 days (data expressed 
as ± s.d and N = 6 animals per group). Histopathological analysis of lung (b), spleen (c), heart (d), kidney (e), 
liver (f) and testis (g) in control, 1 day and 28 days after intraperitoneal administration of the NPs did not show 
any cell and/or tissue damages (the scale bar is 100 μm; blue line).
7Scientific RepoRts |          (2019) 9:6044  | https://doi.org/10.1038/s41598-019-42633-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
total mTOR and phosphorylated-mTOR (p-mTOR) expressions in different groups. Expression of the total mTOR 
protein was not affected by MCAO or Se NPs + MCAO treatments. However, increased p-mTOR expression was 
detected in the MCAO and vehicle groups. Interestingly, OX26 PEG Se NPs treatment before MCAO significantly 
decreased p-mTOR expression (Fig. 5c). This is associated with the neuroprotective effects of the OX26-PEG-Se 
NPs in suppression of mTORC1 complex.
Targeting molecular pathways involved in controlling antioxidant defense system. We also tried to decipher the 
link between total and phosphorylated FoxO1 protein and neuronal survival in different groups. FoxO molecu-
lar targets include different genes coding for both intra and extracellular antioxidant proteins. FoxO1 increases 
transcription of selenoenzymes including glutathione peroxidase 1 (GPx1), and other antioxidant enzymes such 
as superoxide dismutase (SOD) and catalase. Stress-responsive kinases like Akt and ERK catalyze the FoxO1 
phosphorylating that leads to its inactivation and nuclear exclusion40. OX26-PEG-Se NPs treatment before 
MCAO increased the expression of the total FoxO1 protein, while it dramatically decreased the expression of the 
p-FoxO1 protein, suggesting promotion of endogenous antioxidant defenses in rat hippocampal cells (Fig. 6a). 
Cross-talk between FoxO and β-catenin/Wnt pathways has been reported in previous studies. For example, acti-
vated Wnt inhibits the β-catenin degradation that leads to an increase on cytosolic β–catenin protein. Cytosolic 
β–catenin was transferred to the nucleus and interacts with FoxO proteins to promote the expression of the 
antioxidant enzymes such as Mn-SOD41. To examine whether the OX26-PEG-Se NPs may target Wnt/β-catenin 
cellular signaling pathway to induce neuroprotection against oxidative stress was studied in next step. 24 h after 
the MCAO induction, no significant increase in mRNA level of Wnt3a was observed in rat hippocampal tissue as 
compared to control and sham groups. OX26-PEG-Se NPs treatment before MCAO led to a significant increase 
on mRNA level of Wnt3a in hippocampal tissue (Fig. 6b). OX26 PEG Se.
NPs also increased β-catenin mRNA at hippocampal tissue 24 h after MCAO (Fig. 6c). These results strongly 
suggested that the OX26-PEG-Se NPs reinforce the endogenous antioxidant defense by targeting parallel signa-
ling pathways. It has been shown that Repressor element 1 silencing transcription factor (REST) overexpression 
by neurotoxic stimuli confers neuronal survival via a Wnt-dependent mechanism9. One of the components of 
the hippo signaling pathway (Yap1), may directly bind to FoxO1 and promotes its transcriptional activity from 
antioxidant enzymes. The Yap1 down regulation increases the vulnerability of the cells to reactive oxygen species 
(ROS), leading to neuronal cell death42. Confirming the abovementioned data, we found that the Yap1mRNA 
level decreased by MCAO induction. Conversely, the mRNA level of Yap1 dramatically increased relative to other 
groups, 24 h after MCAO in OX26-PEG-Se NPs treated group (Fig. 6d). A previous study reported that pretreat-
ment with 1 mg/kg of rosuvastatin (present in phase II of therapies for acute ischemic stroke in clinical research) 
once a day from 7 days before induction of MCAO decreased I/R injury following ischemic stroke through 
Figure 5. Western extracted data shows expression levels of (a) Tsc1, (b) Tsc2 and p-Tsc2, and (c) mTOR and 
p-mTOR proteins in Wistar rats treated by MCAO + Se NPs as compared to other groups (*p < 0.001 compared 
to control and sham, #p < 0.01 compared to MCAO and vehicle, N = 4 animals per group).
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attenuation of oxidative stress43. Likewise, our finding showed that pretreatment with 2 mg/kg (single dose) of the 
OX26-PEG-Se NPs could activate involved in controlling antioxidant defense system.
Targeting molecular pathways involved in protein quality control. In the ischemic brain tissue activated mTORC1 
also suppresses the activity of the ubiquitin-proteasome system (UPS) that leads to accumulation of the misfolded 
and damaged proteins, and consequently, neuronal cell death. The p-mTORC1 can inhibit the activity of ERK5 
gene acting as the central positive regulator of UPS in mammals44. Hence, the effect of OX26-PEG-Se NPs on the 
USP function in hippocampal cells after MCAO was investigated. Induction of the MCAO slightly decreased the 
mRNA level of ERK5 gene, whereas the OX26-PEG-Se NPs significantly increased ERK5 mRNA. This suggested 
the capability of the OX26-PEG-Se NPs in preserving neuronal cell survival through restoration of UPS activity 
(Fig. 7a). On the other hand, it is well documented that autophagy is a collaborator of UPS in neuroprotection via 
degradation of specific protein aggregates and damaged organelles in neurons. Indeed, UPS mediated degrada-
tion of small and soluble aggregated proteins due to the 26S proteasome and the pore-size limitations of the retro-
translocation channel whereas large misfolded proteins and damaged organelles move to autophagy45. Previous 
evidences have showed that excessive activity of mTORC1 activity results in impairment of mitochondrial elec-
tron transport chain, overgeneration of ROS, suppression of autophagy, and subsequent poor cell survival46. On 
the other hand, accumulating evidences showed that FoxO1 activation regulates autophagy in neurons47. Hence, 
a key question is whether the OX26-PEG-Se NPs contributes to neuronal survival by removing damaged mito-
chondria and large misfolded proteins through an autophagy-dependent mechanism. To clarify this issue, we 
measured mRNA level of ULK1 gene in rat hippocampal tissue by RT PCR assay. The RT-PCR analysis showed 
a decrease in the ULK1 mRNA level 24 h after reperfusion. OX26-PEG-Se NPs administration before MCAO 
significantly increased the ULK1 mRNA level, suggesting protective autophagy induction (Fig. 7b).
Targeting molecular pathways involved in memory consolidation by hippocampal neurons. Cognitive and behav-
ioral outcome of the OX26-PEG-Se NPs treatment after cerebral ischemia was evaluated by studying its effects 
on mTORC2 complex at molecular levels. mTORC2 complex plays a major role in the conversion from short- to 
Figure 6. Western extracted data shows expression levels of (a) cytoplasmic FoxO1 and p-FoxO1 proteins 
in Wistar rats treated by MCAO + Se NPs as compared to other groups (*p < 0.001 compared to control and 
sham, #p < 0.01 compared to MCAO and vehicle, $ p < 0.05 for MCAO + Se NP group as compared to other 
groups, N = 4 animals per group). RT-PCR extracted data shows expression levels of the mRNA level of (b) 
Wnt3a (*p < 0.001 compared to control and sham, and #p < 0.01 compared to MCAO and vehicle), c) β-catenin 
(*p < 0.01 compared to control and sham, and #p < 0.05 compared to MCAO and vehicle), d) Yap1 (*p < 0.001 
compared to control and sham, #p < 0.001 compared to MCAO and vehicle).
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long-term memory and consolidation of long-term memory through regulating of actin polymerization48. Here, 
the impact of OX26-PEG-Se NPs on restoring the rictor (core subunit of mTORC2 complex) mRNA at hip-
pocampal neurons and preserving the cognitive function in rats suffered focal cerebral ischemia was examined. 
Rictor mRNA level was decreased in hippocampal tissues prepared from MCAO and vehicle groups. In contrast, 
the rictor mRNA level significantly increased in hippocampal tissues treated by the OX26-PEG-Se NPs, indicat-
ing recovery of cognitive functions and increase of the activity of mTORC2 (Fig. 7c). It has been reported that 
Donepezil, a clinical neuroprotective drug, attenuates the memory deficit at 5 mg/kg dose for 21 consecutive days 
following a period of cerebral ischemia for 10 minute49. Compared with Donepezil that is in phase II of therapies 
for acute ischemic stroke, this study showed that a short-term therapy (single administration) of OX26-PEG-Se 
NPs with lower dose could activate molecular pathways involved in memory consolidation by hippocampal 
neurons.
Targeting molecular pathways involved in neuronal cell apoptosis. A tight association between mTORC2 and 
hippo signaling pathways has been reported by previous studies. For instance, rictor/mTORC2 decreases the 
extent of the cell loss through Mst1 inhibition50. Mst1 (mammalian Ste20-like kinase 1) is a pro-apoptotic kinase 
and a component of the hippo signaling pathway that increases susceptibility of neurons to the apoptotic cell 
death by improving the interaction between Beclin1 and Bcl-2, and subsequently, suppression of the autophagy51. 
Here, to evaluate the role of Mst1 in the vulnerability of hippocampal neurons, we also assayed mRNA level of 
Mst1 gene. The RT-PCR assay revealed that mRNA level of Mst1 significantly increased following MCAO induc-
tion. OX26-PEG-Se NPs administration before MCAO decreased the Mst1 mRNA level in hippocampal tissue as 
compared to the MCAO and vehicle groups.
To confirm the anti-apoptotic property of the OX26-PEG-Se NPs in rat hippocampal neurons against 
ischemia, we assessed the expression of pro-apoptotic and anti-apoptotic proteins by Western blot assay. 
Increased expression of the pro-apoptotic Bax and cleaved caspase 3 proteins in MCAO group was reversed by 
OX26-PEG-Se NPs administration, indicating the limited apoptotic cell death by functionalized Se NPs (Fig. 8a–
c). In parallel, decreased expression of the anti-apoptotic protein Bcl2 in MCAO group, significantly reversed by 
OX26-PEG-Se NPs treatment, confirming the anti-apoptotic effects of the OX26-PEG-Se NPs. Above mentioned 
Figure 7. (a,b) Intraperitoneal administration of OX26-PEG-Se NPs significantly increased mRNA level 
of ERK5 and ULK1 gene (*p < 0.001 compared to control and sham, #p < 0.001 compared to MCAO and 
vehicle). (c) mRNA level of Rictor significantly decreased in MCAO and vehicle compared to control and sham 
(*p < 0.05). OX26-PEG-Se NPs increased mRNA level ofRictor compared to MCAO and vehicle (#p < 0.001). 
(d) Mst1 exhibited an increased mRNA level in MCAO and vehicle relative to control and sham (*p < 0.05). 
Treatment with OX26-PEG-Se NPs significantly decreased mRNA level of Mst1 compared to MCAO and 
vehicle (#p < 0.01, N = 7 animals per group).
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results show that targeted therapy with OX26-PEG-Se NPs can act similar or better than antiplatelet clinical drugs 
such as aspirin. For instance, aspirin indicated a significantly lower degree of apoptosis in MCAO rats at 100 mg/
kg concentration whereas this study showed that OX26-PEG-Se NPs administration at 1000 ug/ml (2 mg/kg) con-
centration markedly decreased apoptosis52. Likewise, treatment with OX26-PEG-Se NPs at 2 mg/kg dose could 
decrease apoptotic cell death similar to Edaravone, a free radical scavenger drug, at 3 mg/kg dose that is in phase 
II of therapies for acute ischemic stroke53.
Targeting molecular pathways involved in inflammatory responses after stroke. The jak2/stat3 pathway plays an 
important role in various diseases54. Focal cerebral ischemia is often accompanied by activation of macrophages/
microglia, leading to acute inflammatory responses and neuronal damage through aberrant activation of the jak2/
stat3 pathway55. Hence, we also investigated the anti-inflammatory effect of the OX26-PEG-Se NPs by targeting 
Jak2/Stat3 pathways. Using RT-PCR assay, it was found that the MCAO induction led to a significant increase in 
Jak2 mRNA level 24 h after ischemic insult. The expression of Jak2 was markedly suppressed in presence of the 
OX26-PEG-Se NPs (Fig. 9a). We further investigated Stat3 gene expression in different experimental groups. 
Our results showed relatively increased expression of the Stat3 in MCAO and vehicle groups, which have been 
reversed byOX26-PEG-Se NPs treatment, indicating functionalized Se NPs potential on attenuating the inflam-
matory reactions (Fig. 9b). Furthermore, after stroke aberrant expression of some members of the Adamts family 
such as Adamts-1 and -4 by inflammatory cells leads to the extracellular matrix (ECM) breakdown followed by 
neural cell death56. To determine if the OX26-PEG-Se NPs might contribute to maintaining the structural integ-
rity of ECM in rat hippocampal tissue, we measured Adamts-1 mRNA levels in all groups. The Adamts-1 mRNA 
level was elevated by MCAO in the first 24 h after ischemic insult, that it significantly decreased by OX26-PEG-Se 
NPs treatment (Fig. 9c). These findings indicate that the OX26-PEG-Se NPs also protected the ECM integrity that 
plays critical role on preserving neural cell survival during and after stroke. Compared with some neuroprotective 
drugs such as statins that are in phase I therapies for acute ischemic stroke and contribute to reduction of neu-
roinflammation following stroke, OX26-PEG-Se NPs showed similar action with lower dose57. Although Tissue 
plasminogen activator (tPA) is considered the gold standard treatment for ischemic stroke, one of its side effects is 
enhancement of inflammatory response in brain capillaries and subsequently neuronal cell damage after stroke58. 
Figure 8. The expression level of (a) Bax, (b) Caspase3 proteins and (c) Bcl2 24 h after reperfusion. 
Intraperitoneal administration of OX26-PEG-Se NPs could maintain the low level of Bax and cleaved caspase-3 
proapoptic factors under oxidative stress (*p < 0.01 compared to control and sham, #p < 0.001 compared to 
MCAO and vehicle, N = 4 animals per group).
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Compared with tPA, this study showed that the OX26-PEG-Se NPs could inhibit molecular pathways involved in 
inflammatory responses after stroke.
Conclusion
Collectively, we successfully synthesized a biodegradable nanoparticulate system capable of targeting the brain 
for stroke therapy. OX26 antibody surface decoration remarkably enhanced the targeted transport of Se NPs to 
the brain through transferrin receptor-mediated endocytosis. Our in vitro analysis revealed that the major local-
ization of the NPs was in the nucleus. More importantly, we found that Se NPs contributed to neuronal survival 
by targeting different cellular signaling pathways (Fig. 10) that regulate cellular metabolic state (TSC1/TSC2, 
p-mTOR, mTORC1), oxidative defense system (FoxO1, β-catenin/Wnt, Yap1), inflammatory reactions (jak2/
stat3, Adamts-1), autophagy and apoptotic cell death (Mst1, ULK1, Bax, Caspase-3 and Bcl-2), as well as func-
tional properties of the hippocampal neurons (rictor/mTORC2).
Methods and Materials
Preparation of OX26-PEG-coated Se NPs. Here, we describe our synthesis protocol for preparation of 
selenium nanoparticles (NPs) with selenium core and polyethylene glycol (PEG) surface coating. Initially, 2 μg/
mL poly (ethylene glycol)-carboxylic acid functionalized (average Mw 5 kDa, Sigma- Aldrich) was directly mixed 
with 1800 μL of 0.1 M selenious acid 98% (Sigma-Aldrich) in 10 mL deionized (DI) water, by constant stirring. 
Then, 3 mL of aqueous 0.1 M ascorbic acid solution (A92902, Sigma-Aldrich) was added dropwise and the result-
ing solution was stirred at room temperature. After 30 min, 20 μL EDC/NHS (Sigma-Aldrich) (75 mM/30 mM, 
v/v, 1:1) solutions was directly added into the Se-containing solution and the mixture was stirred for 30 min. After 
washing by DI water, 5 μL of CD71 antibody (OX26) (Santa Cruz Biotechnology) was added into Se suspension 
and the mixture was stirred at room temperature for 5 h. The non-bonded OX26 antibodies were removed by 
centrifugation at 20,000 rpm for 60 min at 4 °C. Then, the pellets were resuspended in Milli-Q water. To evaluate 
the impact of NP-protein interactions on cellular uptake and survival in vitro, FITC (Fluorescein isothiocyanate) 
- OX26 (Santa Cruz Biotechnology) was used instead of CD71 antibody (OX26).
Material characterizations. The size distribution and zeta potential of the OX26-PEG-Se NPs were 
evaluated by a Nano-ZS instrument (Malvern Zeta sizer Nano ZS90, Worcestershire, UK) in water, phosphate 
Figure 9. The mRNA level of (a) Jak2 and (b) Stat3 (*p < 0.001 compared to control and sham and #p < 0.001 
compared to MCAO and vehicle), and (c) Adamts-1 (*p < 0.001 compared to control and sham, and #p < 0.001 
compared to MCAO and vehicle) genes of Wistar rats suffered focal cerebral ischemia, 24 h after treating by 
OX26-PEG-Se NPs (for all tests, N = 7 animals per group).
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buffered, human plasma, and the complete cell culture medium (cMEM) consisting of MEM (supplemented with 
10% fetal calf serum (Gibco), 1% penicillin/streptomycin (Gibco) at 25 °C and 37 °C. Particle morphology and 
localization were determined by transmission electron microscopy (TEM, H-7650) at an accelerating voltage 
of 80 KV. For evaluation of morphology, a droplet of diluted nanoparticles was dropped onto carbon-coated 
copper grids, (some of them were also prepared by using a desktop sputtering system (Nanostructured Coating 
Co., Iran). Then, the samples were dried at room temperature for two days. To evaluate neuronal localization of 
OX26-PEG-Se NPs, differentiated PC12 cells were exposed to the NPs (with sizes ~25 nm and concentration of 
~100 μg/mL) at 37 °C for 1 h and 3 h. The RPMI media was removed and the cells were washed twice with PBS 
buffer and harvested with trypsin/EDTA for 4 min. Then, the cells were fixed at room temperature in 2.5% glutar-
aldehyde in 0.1 M Sorensen phosphate buffer (pH 7.4) for 2 h and washed with buffer (pH 7.3). Then, 1% osmium 
tetroxide (in DI water) was used to postfix the samples for 2 h. After that, the cells were dehydrated in increasing 
concentrations of ethanol (from 70% up to 100%), and transferred to copper grids following several sequential 
steps of (i) immersion in an ethanol/Epon (1:1 vol/vol) mixture for 1 h, (ii) transferring and embedding in pure 
Epon at 37 °C for 2 h, (iii) polymerization at 40 °C for 72 h and (iv) preparation of ultrathin sections of 100 nm 
thickness by ultramicrotome. Then, the cells were stained with uranyl acetate and lead citrate.
Quantitation of OX26 antibody Conjugated to SeNPs. Bradford assay was used to evaluate the num-
ber of immobilized OX26 antibody molecules onto the surface of SeNPs. In brief, standard solutions of OX26 
antibody (1, 5 and 10 μg/mL) were provided in 2 mM borate buffer (pH 8.0). The standard solutions and OX26 
conjugated nanoparticles were centrifuged at 5000 g for 5 minutes. Then, 90 μL of the standard solutions or the 
supernatant was transferred to a 96-well plate. After dilution of each sample and standard with 70 μL of 2 mM 
borate buffer, 40 μL of the Bio-Rad reagent was added to each well. After 15 minutes incubation at room temper-
ature, UV−visible absorption was determined at 595 nm to quantify OX26 antibody in the supernatant. Finally, 
total number of immobilized OX26 antibody molecules onto the surface of SeNPs was calculated as the difference 
between the number of OX26 antibody molecules added to the SeNP suspension and antibody remaining in the 
supernatant.
Cell culture. In order to obtain the required cell density, cells were counted before each experiment. PC12 
cells (original batches from Pasteur Institute of Iran), were isolated from a transplantable rat adrenal pheochro-
mocytoma. In order to study neurobiological mechanisms, PC12 cells were cultured in RPMI 1640 medium 
supplemented with 10% fetal calf serum (Gibco), 1% penicillin/streptomycin at 37 °C in a humidified 5% CO2 
atmosphere. To induce neuronal differentiation, cells were treated with NGF and 1% serum (1:100) for 5 days 
(50). The human MCF7 breast adenocarcinoma cells (original batches from Pasteur Institute of Iran) were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin at 37 °C in a humidified incubator with 5% CO2 atmosphere.
oxygen glucose deprivation. The OGD was induced in human MCF7 cells and rat pheochromocy-
toma (PC12) cells (under differentiation state) through immersion in 500 μL deoxygenated custom neurobasal 
medium without glucose, aspartate, glutamate, glutamine or pyruvate (Invitrogen). Oxygen was removed the 
immersion solution by a premixed gas (85% N2, 10% H2, 5% CO2) within 30 min. Following OGD, both human 
MCF7 cells and rat PC12 cells were randomized into two groups (SF and cMEM) and incubated with 25 μg/
mL FITC-OX26-PEG-coated SeNPs in oxygen-glucose deprivation/reperfusion condition at different times. 
Fluorescence microscope was used to evaluate cellular uptake and survival at different times.
Figure 10. Proposed signaling pathways involved in SeNPs-induced protection.
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Flow cytometry. To do this, 3 × 105 cells were resuspended in a given volume of cMEM and into individ-
ual cell-culture-flask (25 cm). 5flasks of differentiated PC12 cells were exposure to FITCPEG-coated Se NPs for 
given times. To evaluate the impact of OX26-PEG-coated Se NPs on targeting capability by flow cytometry, after 
exposing the NPs to the cells for the required times, the NP suspension was removed, then the cells were washed 
twice with PBS buffer and harvested with trypsin/EDTA for 4 min. Formaline 4% solution (Sigma) was used to fix 
cells for 20 min. Finally, the cells were resuspended in PBS buffer for flow cytometry assay. In parallel, 5 flasks of 
differentiated PC12 cells were also incubated with FITC-OX26-PEG-coated Se NPs, with the same experimental 
conditions.
Fluorescence microscopy. For qualitative analysis of the impact of NP-protein interactions on cellular 
uptake and survival, MCF7 cells were allowed to attach for 24 h as described above (in DMEM supplemented 
with 10% FBS). Then the medium was removed from the cell-culture-flask and after washing the cells three times 
with cold PBS buffer, an individual incubation of FITC-OX26-PEG-coated Se NPs in SF and the cMEM was 
performed for different periods of time. Then, the cells were washed three times with cold PBS buffer to remove 
the OX26-PEG-coated Se NPs from outside of the cells. Cellular uptake and survival were then investigated by 
fluorescence microscope (Nikon Eclipse 230 80i).
ICp-oes analysis. This analysis was used to determine the Se content in different tissues of male Wistar rats 
after intraperitoneal administration of PEG-coated Se NPs and Ox26-PEG-coated SeNPs after 24 h exposure. The 
brain, liver and kidney tissue samples were collected, weighed and homogenized for 5 min in 3 mL cold PBS with 
a tissue homogenizer. Then, samples were digested with nitric acid and hydrogen peroxide (4:1, v/v) at 70 °C for 
6 min. The samples were cooled at room temperature and transferred to 15 mL ICP-OES tubes. All samples were 
analyzed in triplicate.
ethical approval. The present study was conducted in strict accordance with the Guide for the Care and 
Use of Laboratory Animals published by National Research Council of the National Academies, USA (2011) and 
was approved by the Institutional Animal Ethical Committee of Iran University of Medical Science. Nine weeks 
old Male Wistar rats weighing 250–300 g were purchased from the Center for Experimental Animals of Iran 
University of Medical Science. Animals were kept in the temperature controlled room under a 12/12 h light/dark 
with unlimited access to food and water. To maintain social interaction, rats were placed in four per cage. They 
were randomly subdivided into 5 groups: a control group of healthy mice (normal, n = 12), sham operated control 
group (sham, n = 12), MCAO group (MCAO, n = 12), OX26-PEGantibodygroup (Vehicle, n = 12), MCAO-Se 
NPs group (treatment, n = 12).
MCAo model. Rats were anesthetized with intraperitoneal injection of a mixture of ketamine and xylazine. 
The right common carotid artery (CCA) was exposed via a midline neck incision; then after isolation of external 
carotid artery (ECA) and internal carotid artery (ICA), ECA was tied. To occlude the MCA, a 4–0 monofilament 
nylon suture was inserted from the right CCA to the ICA. After 30 min, monofilament was gently removed to 
allow recirculation of cerebral blood flow for 22 h. All above procedures were repeated for sham-operated animals 
except occlusion of the MCA. Intraperitoneal administration (1000ug/ml) of OX26-PEG-coated Se NPs was per-
formed 1 h before ischemic stroke.
tissue preparation. Rats were sacrificed under deep anesthesia with a mixture of ketamine/xylazine (final 
dose: 30/10 mg/kg body weight, IP). The rat brains were removed; then the ipsilateral ischemic hippocampus was 
quickly dissected from the brain tissue and saved at −80 °C prior to RT-PCR and Western blot assays.
Real time Rt–pCR. Real-time PCR was run for 45 cycles. Single peak melting curves were described as 
determinants of purity. In order to extract RNA, frozen hippocampus tissue was powdered in a mortar and pestle 
by the addition of liquid nitrogen; then homogenized in TRIzol (Invitrogen) on ice for 5 minute. The samples 
were incubated with 250 mL chloroform (Sigma-Aldrich) for 3–5 min at room temperature and centrifuged at 
13,000 g for 20 min at 4 °C. Afterward, the upper aqueous phase containing the RNA was separated and incu-
bated with an equal volume of cold isopropanol (Sigma-Aldrich) overnight at −20 °C, followed by centrifuging 
at 13,000 g for 11 min at 4 °C. Finally, the pellets were mixed with 75% ethanol and centrifuged at 7,700 g for 
6 min at 4 °C. Ethanol was removed and pellet dissolved in 25 μL of DEPC-treated H2O. The RNA was stored at 
−80 °C prior to cDNA synthesis. The RNA purity and concentration were determined at 260/280 nm by using 
a Nanodrop spectrophotometer (NANO DRAP oNEC, Thermo Scientific). The RNA series were converted to 
cDNA ones by a Dart cDNA kit (EURx Company, Poland) according to the manufacturer’s protocol. Real-time 
PCR was performed using SYBR®.
Premix Ex Taq ™ II (TliRNaseH Plus, RR820Q) (TAKARA). The detection of PCR products was based on the 
DNA-binding dye SYBR Green. Temperature cycling was 94 °C for 30 s, 56 °C for 30 s, and 68 °C for 1 min and 
repeated for 45 cycles. 2 − ΔΔCT method was used to calculate relative changes in gene expression. Results were 
reported as arbitrary units. Serial dilution of titrated product was performed to generate a standard curve for each 
primer pair. Internal control used for this study was GAPDH. Primers used in present study are listed in Table S6.
Western blot assay. Frozen hippocampus tissue was homogenized in RIPA buffer (protease and phos-
phatase inhibitor) (Sigma-Aldrich). After a sonication step, right hippocampus lysate was subjected to centrif-
ugation at 13300 g at 4 °C for 20 min. The supernatant was removed and protein concentration was determined 
using the Nanodrop equipment. Then, 4–20% gradient SDS/PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) was used to separate soluble protein (50 μg). Separated soluble proteins were transferred onto 
PVDF (Immobilon®-FL PVDF membrane pore size 0.45 μm-Sigma-Aldrich). To evaluate the loading, PVDF 
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membranes were stained with Sypro or Ponceau S. Then, nonspecific reaction sites were blocked with a blocking 
solution (3% solution of BSA and 0.1% Tween-20 (TBST)). The antibodies used for this experiment are listed 
in Table S7. After incubation with primary antibodies, PVDF membranes were exposed to diluted secondary 
antibody in blocking buffer for 1 h at room temperature. Then, chemiluminescent HRP Substrate (Millipore) was 
served as detector of immunoreactivity onto Kodak X-OMAT films for 5 min. β-Actin served as loading control. 
To evaluate the mean values of proteins, ratio of expression of each protein to the expression of the β-actin in the 
same sample was determined by Alpha Ease ® FC Imaging System based on their optical densities.
statistical analysis. Experiments were carried out in duplicates or triplicates and the results are shown as 
Mean ± standard deviation (SD). The statistical analysis of data was performed using prism 5. To analyze the 
difference between two groups, two-tailed Student’s t-test was served and the differences between three or more 
groups were performed by one-way ANOVA. Values of P < 0.05 were considered to denote statistical significance 
in all cases.
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